PT  - JOURNAL ARTICLE
AU  - Tillmann, Hans L.
AU  - Suzuki, Ayako
AU  - Merz, Michael
AU  - Hermann, Richard
AU  - Rockey, Don C.
TI  - A Novel Computer-Assisted Drug-Induced Liver Injury Causality Assessment Tool (DILI-CAT)
AID  - 10.1101/2021.03.05.21252982
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.05.21252982
4099  - http://medrxiv.org/content/early/2021/03/08/2021.03.05.21252982.short
4100  - http://medrxiv.org/content/early/2021/03/08/2021.03.05.21252982.full
AB  - Objective We hypothesized that a drug-characteristic DILI-phenotype could be defined and be used to develop a computer-assisted DILI causality assessment-tool (DILI-CAT).Design A drug-specific DILI-phenotype was developed for amoxicillin-clavulanate (AMX/CLA), cefazolin, cyproterone, and polygonum multiflorum using data from published case series, and subsequently a DILI-CAT Score (DILI-CAT-S) was created for each drug. The phenotype was made up of the following three parameters: (1) latency, R-value, and (3) AST/ALT ratio (also de Ritis ratio). A point allocation system was developed with points allocated depending on the degree of deviation from the core of published data for the three phenotypic parameters.Results The four drugs had a significantly different phenotype based on the three parameters utilized. For example, the median cyproterone latency was 150 days versus less than 43 days for the other three drugs (median: 26 for AMX/CLA, 20 for cefazolin, and 20 days for polygonum multiflorum; p<0·001). The R-value for the four drugs was also significantly different (median: cyproterone [12.4] and polygonum multiflorum [10.9]) from AMX/CLA (1.44) and cefazolin (1.57; p<0.001). The resulting DILI-CAT-S effectively separated cyproterone and polygonum multiflorum from AMX/CLA and cefazolin, respectively (p<0·001). Notably, because of overlap in phenotype AMX/CLA and cefazolin could not be differentiated by DILI-CAT-S.Conclusion DILI-CAT is a data-driven, diagnostic tool built to define drug-specific phenotypes. Data presented here provide proof of principle that a drug-specific, data-driven causality assessment tool can be developed for different drugs and raise the possibility that such a process could improve and standardize causality assessment methods.Funding DCR was supported by the NIH, grant P30 DK 123704Competing Interest StatementHans L. Tillmann is a stockholder of Abbott, AbbVie, and Gilead outside the submitted work. He reports that his wife is a full-time employee of AbbVie. Ayaka Suzuki has nothing to disclose. Michael Merz has nothing to disclose. Richard Hermann is a full-time employee and stockholder at AstraZeneca. Don C. Rockey has nothing to disclose.Clinical Trialn.a. not a clinical trialFunding StatementDon C. Rockey was supported by the NIH, grant P30 DK 123704Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB was required for the analysis of published case seires.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnalysis only includes publicly available data. https://doi.org/10.1111/liv.12899 https://doi.org/10.1016/s0016-5085(99)70404-x https://doi.org/10.1016/j.cgh.2014.11.036 https://doi.org/10.1016/j.ctim.2013.12.008